Eva Ciruelos

Research Institute Hospital 12 de Octubre — Spain

Medicine · Health Sciences

54h-index18.9kcitations691works2.82yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Advanced Breast Cancer Therapies(381), HER2/EGFR in Cancer Research(248), Cancer Treatment and Pharmacology(187), Breast Cancer Treatment Studies(125), Cancer Genomics and Diagnostics(102)

Publications690 total

Transcriptomic Predictors of Survival for Palbociclib + Endocrine Therapy Versus Capecitabine in Aromatase Inhibitor-Resistant Breast Cancer From the GEICAM/2013-02 PEARL Trial.
UNC Libraries·2025Open Access
Palbociclib, Trastuzumab, and Endocrine Therapy in Pretreated HER2-Positive and PAM50 Luminal Advanced Breast Cancer: Randomized Phase II, SOLTI-1303 PATRICIA Trial
Clinical Cancer Research·2025
Addition of Ipatasertib to Dual Anti-HER2 Maintenance Therapy in HER2-Positive Metastatic Breast Tumors with <i>PIK3CA</i> Mutations: The Phase Ib SOLTI-1507 IPATHER Trial
Clinical Cancer Research·2025· 1 citedOpen Access
Associations of the HER2DX Genomic Test with Biological and Pathologic Features in HER2-Positive Breast Cancer
Clinical Cancer Research·2025Open Access
SEOM-GEICAM-SOLTI clinical guidelines for early-stage breast cancer (UPDATE 2025)
Clinical & Translational Oncology·2025Open Access
Supplementary Table S8 from Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients
2025Open Access
Supplementary Table S1 from &lt;i&gt;CCNE1&lt;/i&gt; and &lt;i&gt;PLK1&lt;/i&gt; Mediate Resistance to Palbociclib in HR+/HER2− Metastatic Breast Cancer
2025Open Access
Supplementary Figure S3 from &lt;i&gt;CCNE1&lt;/i&gt; and &lt;i&gt;PLK1&lt;/i&gt; Mediate Resistance to Palbociclib in HR+/HER2− Metastatic Breast Cancer
2025Open Access
Supplementary Figure S10 from &lt;i&gt;CCNE1&lt;/i&gt; and &lt;i&gt;PLK1&lt;/i&gt; Mediate Resistance to Palbociclib in HR+/HER2− Metastatic Breast Cancer
2025Open Access
Supplementary Table S1 from Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients
2025Open Access
Supplementary Figure S11 from &lt;i&gt;CCNE1&lt;/i&gt; and &lt;i&gt;PLK1&lt;/i&gt; Mediate Resistance to Palbociclib in HR+/HER2− Metastatic Breast Cancer
2025Open Access
Supplementary Table S13 from Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients
2025Open Access
Supplementary Table S2 from &lt;i&gt;CCNE1&lt;/i&gt; and &lt;i&gt;PLK1&lt;/i&gt; Mediate Resistance to Palbociclib in HR+/HER2− Metastatic Breast Cancer
2025Open Access
Supplementary Figure S9 from &lt;i&gt;CCNE1&lt;/i&gt; and &lt;i&gt;PLK1&lt;/i&gt; Mediate Resistance to Palbociclib in HR+/HER2− Metastatic Breast Cancer
2025Open Access
Supplementary Figure S6 from &lt;i&gt;CCNE1&lt;/i&gt; and &lt;i&gt;PLK1&lt;/i&gt; Mediate Resistance to Palbociclib in HR+/HER2− Metastatic Breast Cancer
2025Open Access
Supplementary Figure S2 from &lt;i&gt;CCNE1&lt;/i&gt; and &lt;i&gt;PLK1&lt;/i&gt; Mediate Resistance to Palbociclib in HR+/HER2− Metastatic Breast Cancer
2025Open Access
Supplementary Table S7 from Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients
2025Open Access
Supplementary Figure S4 from Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients
2025Open Access
Supplementary Table S4 from Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients
2025Open Access
Supplementary Table S12 from Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients
2025Open Access
page 1 of 35Next →

Frequent Co-authors

Javier Cortés(12), Marco Colleoni(9), Mario Campone(8), Andreas Schneeweiß(8), Begoña Bermejo(8), Aleix Prat(8), Mafalda Oliveira(8), Semiglazov Vf(7), Eric P. Winer(7), Meredith M. Regan(7), Prudence A. Francis(7), Giuseppe Viale(7), Fabio Puglisi(7), Tomás Pascual(7), Laia Paré(7), Eduardo Martínez de Dueñas(7), José Baselga(6), Luca Gianni(6), Harold J. Burstein(6), Gini F. Fleming(6)